RECENT GENERAL PUBLICATIONS


2012

Brindley D.A., Davie N.L., Culme-Seymour E.J., Mason C., Smith D.W. & Rowley J.A. (2011). Peak serum: implications of serum supply for cell therapy manufacturing. Regenerative Medicine, Jan 2012, Vol. 7(1), 7-13.


2011

Mason C., Brindley D.A., Culme-Seymour E.J. and Davie N.L. (2011). Cell Therapy Industry: billion dollar global business with unlimited potential. Regenerative Medicine, May 2011, Vol. 6(3), 265-272.

Brindley, D.A., Reeve, B.C., Sahlman, W.A., Bonfiglio, G.A., Davie N.L., Culme-Seymour E.J. and Mason C., (2011). The impact of market volatility on the Cell Therapy Industry. Cell Stem Cell, Nov. 2011, Vol. 9(5), 397-401.


2010

Mason C. and Manzotti E. (2010). Stem cell nations working together for a stem cell world. Regenerative Medicine, Jan 2010, Vol. 5(1), 1-4.

Mason C. and Manzotti E. (2010). The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine. Regenerative Medicine, March 2010, Vol. 5(2), 153-155.

Mason C. and Manzotti E. (2010). Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regenerative Medicine, May 2010, Vol. 5(3), 307-313.

Mason C. and Manzotti E. (2010). Defeating stem cell tourism. Regenerative Medicine, May 2010, Vol. 5(5), 681-686.


2009

Mason C. and Manzotti E. (2009). New era dawns for US stem cell research. Regenerative Medicine, Jan 2009, Vol. 4(1), 1.

Mason C. and Manzotti E. (2009). Revolutionary therapies for diabetes – catalysts for change. Regenerative Medicine, March 2009, Vol. 4(2), 143-146.

Mason C. and Dunnill P. (2009). Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors. Regenerative Medicine, March 2009, Vol. 4(2), 153-157.

Mason C. and Manzotti E. (2009). Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle. Regenerative Medicine, May 2009, Vol. 4(3), 329-331.

Mason C. and Manzotti E. (2009). ‘The Little Purple Book’: BSI Glossary of Regenerative Medicine. Regenerative Medicine, July 2009, 4(4), 483-484.

Mason C. and Manzotti E. (2009). Bioaesthetics and regenerative medicine. Regenerative Medicine, Sept. 2009, Vol. 4(5), 635-637.

Mason C. (2009). ISSCR 2009 Industry Panel Session: Promoting Translation and Commercialization. Cell Stem Cell, Oct. 2009, Vol. 5(4), 379-384.

Mason C. and Manzotti E. (2009). Regen: the industry responsible for cell-based therapies. Regenerative Medicine, November 2009, 4(6), 783-785.

Mason C. and Dunnill P. (2009). Assessing the value of autologous and allogeneic cells for regenerative medicine. Regenerative Medicine, Nov. 2009, Vol. 4(6), 835-853.


2008

Mason C. and Dunnill P. (2008). Stem cell prospects. New Scientist (Letter). 26th January.

Mason C. and Dunnill P. (2008). A brief definition of regenerative medicine. Regenerative Medicine. 3(1) 1–5.

Mason C. and Dunnill P. (2008). The strong financial case for regenerative medicine and the regen industry. Regenerative Medicine. 3(3) 351-363.

Mason C. and Dunnill P. (2008). The crucial linkage required between regenerative medicine bioprocessors and clinicians. Regenerative Medicine. 3(4) 435-442.

Mason C. and Dunnill P. (2008). The need for a regen industry voice. Regenerative Medicine. 3(5) 621-631.
Please leave comments + suggestions on Lee Buckler’s Cell Therapy Blog - “Regenerative Medicine Industry in Need of a Voice?”


2007

Mason C. (2007). Regenerative Medicine 2.0 (RegenMed 2.0) Regenerative Medicine. 2(1), 11-18.

Mason C. and Hoare M. (2007). Regenerative Medicine Bioprocessing: Building a Conceptual Framework Based on Early Studies. Tissue Engineering 13(2), 301-311.

Mason C. (2007). Regenerative Medicine - The Industry Comes of Age. Medical Device Technology. March/April 2007, 25-28.

Mason C. and Dunnill P. (2007). Translational Regenerative Medicine Research: Essential to Discovery and Outcome. Regenerative Medicine 2(3), 227-229.

West M.D. and Mason C. (2007). Mapping the human embryome: 1 to 10e13 and all the cells in between. Regenerative Medicine 2(4), 329-333.

Stephenson E.L., Braude P.B. and Mason C. (2007). International community consensus standard for reporting derivation of human embryonic stem cell lines. Regenerative Medicine. 2(4), 349-362.

Mason C. and Dunnill P. (2007). Good for UK health and wealth. Innovation UK, 28-31.

Mason C. and Dunnill P. (2007). Lessons for the nascent regenerative medicine industry from the biotech sector. Regenerative Medicine. 2(5), 753-756. (Includes the definition of the term, "regen")


2006

Mason C. (2006). Other approaches to fighting cardiovascular disease: Stem cells and engineered tissue. Medical Device Technology. 17(1), 26-27.

Mason C. (2006). The Korean stem cell fiasco: Shifting the focus. Medical Device Technology. 17(2), 24-26.

Mason C. (2006). Stem Cells: The blue print for the future. Medical Device Technology. 17(3), 32-33.

Mason C. (2006). The time has come to engineer tissues and not just tissue engineer. Regenerative Medicine. 1(3), 303-306.

Mason C. and Hoare M. (2006). Regenerative Medicine Bioprocessing: The need to learn from the experience of other fields. Regenerative Medicine. 1(5), 615–623.

Mason C. (2006). A blueprint for the future. Innovation UK. 50-51.

Stephenson E.L., Braude P.B. and Mason C. (2006) Proposal for a universal minimum information convention for the reporting on the derivation of human embryonic stem cell lines. Regenerative Medicine. 1(6), 739-750.

DTI Global Watch Mission Report - "Advanced cell & tissue therapies - A mission to the US" September 2006.


2005

Mason C. (2005). Stem cells are big news, but are they big business? Medical Device Technology, 16(8), 25.

Mason C. (2005). Regenerative medicine: Revolution in the making. Medical Device Technology, 16(9), 22.

Mason C. (2005). Tissue Engineering: A paradigm shift in wound care. Medical Device Technology. 16(10), 32-33.


2004

Mason C. (2004). A bitter lesson, but tissue engineering learns to refocus on commercial realities. Clinica World Medical Device & Diagnostic News 1094, 14.


2003

Mason C. (2003). Tissue engineering. Biotechnology Investment Today, 2(1), 20-26.

Mason C. (2003). Why all the interest in tissue-engineered blood vessel. Biotechnology Investment Today, 2(1), 22-23.

Mason C. (2003). How to tissue engineer. Biotechnology Investment Today, 2( 1), 25.

Mason C. (2003). The future lies in automation. Biotechnology Investment Today, 2(1), 26-27.

Mason C. (2003). Automated tissue engineering: A major paradigm shift in healthcare. Medical Device Technology, 14(1), 16-18.

Mason C. (2003). The age of regenerative medicine. BioCommerce Data’s Biotechnology Compendium 2003/4, 1-3.


2002

Mason C. (2002). Regenerative Medicine: Biotechnology’s opportunity to cure heart disease. BioCommerce Data’s Biotechnology Compendium 2002/3, 21-35.

Mason C. (2002). Coronary Heart Disease. Biotechnology Investment Today, 2, 44-50.

Mason C. (2002). Tissue Engineering. Biotechnology Investment Today, 2, 46.


2001

Mason C. and Bennett L.D. (2001). Tissue engineering. BioCommerce Data’s Biotechnology Compendium 2001/2, 41-44.